Landon Trost, MD, on how he’s refined his use of CCH in Peyronie disease

In this video from the 2024 Sexual Medicine Society of North America Fall Scientific Meeting, Landon Trost, MD, explains what he’s learned from using clostridium collagenase histolyticum (Xiaflex) for treating Peyronie disease. Trost is the founder and director of the Male Fertility and Peyronie’s Clinic in Orem, Utah.

Transcription:

What lessons have you learned over the years from using clostridium collagenase histolyticum (Xiaflex) for treating Peyronie disease?

As with any drug, I think there's a big learning curve that comes anytime something's approved. When it first comes out, everybody copies the FDA-type protocols to try to administer it. But as time has gone on, we found there are definitely better ways to give the drug and to get more effective results. Some of the key things we've learned over time is that you need to do injections back to back. We've learned you need to get an erection with the first injection each series. We've increased the dosage. We found the correct dilution for it. We've seen the importance of adding mechanical traction to it, as well as in-office modeling, and all of these things have resulted in almost a tripling of outcomes since the drug was officially approved. So, as with anything, things just get more and more optimized over time, and this drug is no different.

This transcript was AI generated and edited by human editors for clarity.